Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Willingness to use tamoxifen to prevent breast cancer among diverse women.

Kaplan CP, Kim SE, Wong ST, Sawaya GF, Walsh JM, Pérez-Stable EJ.

Breast Cancer Res Treat. 2012 May;133(1):357-66. doi: 10.1007/s10549-012-1960-5.

2.

Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.

Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH.

J Natl Cancer Inst. 2003 Apr 2;95(7):526-32.

PMID:
12671020
3.

Colorectal cancer screening: what do women from diverse ethnic groups want?

Walsh JM, Kim SE, Sawaya G, Kaplan CP, Wong ST, Gregorich SE, Pérez-Stable EJ.

J Gen Intern Med. 2013 Feb;28(2):239-46. doi: 10.1007/s11606-012-2210-6.

4.

"I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction.

Paterniti DA, Melnikow J, Nuovo J, Henderson S, DeGregorio M, Kuppermann M, Nease R.

Ethn Dis. 2005 Summer;15(3):365-72.

PMID:
16108294
5.

Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.

Melnikow J, Paterniti D, Azari R, Kuenneth C, Birch S, Kuppermann M, Nuovo J, Keyzer J, Henderson S.

Cancer. 2005 May 15;103(10):1996-2005.

6.

Racial and ethnic differences in HPV knowledge, attitudes, and vaccination rates among low-income African-American, Haitian, Latina, and Caucasian young adult women.

Pierre Joseph N, Clark JA, Mercilus G, Wilbur M, Figaro J, Perkins R.

J Pediatr Adolesc Gynecol. 2014 Apr;27(2):83-92. doi: 10.1016/j.jpag.2013.08.011.

7.

Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients.

Kaplan CP, Nápoles AM, Narine S, Gregorich S, Livaudais-Toman J, Nguyen T, Leykin Y, Roach M, Small EJ.

Contemp Clin Trials. 2015 Nov;45(Pt B):443-8. doi: 10.1016/j.cct.2015.09.023.

PMID:
26435199
8.

Variations in breast cancer screening and health behaviors by age and race among attendees of women's health clinics.

Wilson DB, McClish D, Tracy K, Quillin J, Jones R, Bodurtha J.

J Natl Med Assoc. 2009 Jun;101(6):528-35.

PMID:
19585920
9.

Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

Levine M, Moutquin JM, Walton R, Feightner J; Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer..

CMAJ. 2001 Jun 12;164(12):1681-90. Review.

10.

Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.

Fagerlin A, Dillard AJ, Smith DM, Zikmund-Fisher BJ, Pitsch R, McClure JB, Greene S, Alford SH, Nair V, Hayes DF, Wiese C, Ubel PA.

Breast Cancer Res Treat. 2011 Jun;127(3):681-8. doi: 10.1007/s10549-011-1450-1.

11.

Breast cancer anxiety's associations with responses to a chemoprevention decision aid.

Dillard AJ, Scherer L, Ubel PA, Smith DM, Zikmund-Fisher BJ, McClure JB, Greene S, Stark A, Fagerlin A.

Soc Sci Med. 2013 Jan;77:13-9. doi: 10.1016/j.socscimed.2012.10.009.

12.

The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation.

Metcalfe KA, Snyder C, Seidel J, Hanna D, Lynch HT, Narod S.

Fam Cancer. 2005;4(2):97-103.

PMID:
15951959
13.

National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities.

McCaskill-Stevens W, Wilson JW, Cook ED, Edwards CL, Gibson RV, McElwain DL, Figueroa-Moseley CD, Paskett ED, Roberson NL, Wickerham DL, Wolmark N.

Clin Trials. 2013 Apr;10(2):280-91. doi: 10.1177/1740774512470315.

14.

The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial.

Kinney AY, Richards C, Vernon SW, Vogel VG.

Prev Med. 1998 Sep-Oct;27(5 Pt 1):713-9.

PMID:
9808803
15.

Patient reluctance toward tamoxifen use for breast cancer primary prevention.

Port ER, Montgomery LL, Heerdt AS, Borgen PI.

Ann Surg Oncol. 2001 Aug;8(7):580-5.

PMID:
11508619
16.

Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.

Goldenberg VK, Seewaldt VL, Scott V, Bean GR, Broadwater G, Fabian C, Kimler B, Zalles C, Lipkus IM.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):1032-4.

17.

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.

Freedman AN, Yu B, Gail MH, Costantino JP, Graubard BI, Vogel VG, Anderson GL, McCaskill-Stevens W.

J Clin Oncol. 2011 Jun 10;29(17):2327-33. doi: 10.1200/JCO.2010.33.0258. Erratum in: J Clin Oncol. 2013 Nov 10;31(32):4167.

18.

Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.

Fagerlin A, Zikmund-Fisher BJ, Nair V, Derry HA, McClure JB, Greene S, Stark A, Hensley Alford S, Lantz P, Hayes DF, Wiese C, Claud Zweig S, Pitsch R, Jankovic A, Ubel PA.

Breast Cancer Res Treat. 2010 Feb;119(3):613-20. doi: 10.1007/s10549-009-0618-4.

19.
20.

Breast cancer risk in primary care: implications for chemoprevention.

Lewis CL, Kinsinger LS, Harris RP, Schwartz RJ.

Arch Intern Med. 2004 Sep 27;164(17):1897-903.

PMID:
15451765
Items per page

Supplemental Content

Support Center